Amphastar Pharmaceuticals, Inc. (AMPH) Stock Price & How to Invest

Last updated November 2026

Short answer

Amphastar is a California maker of hard-to-produce injectables, inhalers and nasal products whose earnings lean on BAQSIMI nasal glucagon and Primatene MIST. After a record Q3 2026 (revenue ~$207.6 million, adjusted EPS $1.14 against ~$0.86 expected), the stock closed at $28.15 on November 20, 2026, up about 28% in three months and about 8.4x forward earnings. Legacy price erosion, the July 2026 FDA warning letter at its South El Monte plant and a 2027-dated insulin pipeline explain why most analysts sit at Hold with an average target near $24.50, below the price.

AMPH stock price

As of 2026-11-20, Amphastar Pharmaceuticals, Inc. (AMPH) last closed at $28.25, up 8.6% over the past year. Over the past 52 weeks it has traded between $16.87 and $29.71.

AMPH last close
$28.25
1 day
+0.50%
1 month
+7.82%
1 year
+8.61%
52-week range
$16.87 to $29.71
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Amphastar Pharmaceuticals, Inc.'s investor relations page. Walnut is informational, not investment advice.

AMPH key stats

At $28.25 on November 20, 2026, Amphastar Pharmaceuticals, Inc. (AMPH) has a market cap of $1.2B and a P/E of 13.0 on trailing earnings (8.4 on forward earnings).

Market cap
$1.2B
P/E (trailing)
13.0
P/E (forward)
8.4
EPS (trailing 12 months)
$2.18
Price to book
1.5
Beta
0.94

Market cap, P/E and yield are measured at the $28.25 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Amphastar Pharmaceuticals, Inc. (AMPH)?

The last two weeks for Amphastar Pharmaceuticals, Inc., as of November 22, 2026: the price move, the next earnings date, and what analysts changed.

  • AMPH closed at $28.25 on November 20, 2026, down 3.8% over the past five trading days (from $29.37).

Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Amphastar Pharmaceuticals, Inc. (AMPH) do?

Amphastar Pharmaceuticals (Nasdaq: AMPH), based in Rancho Cucamonga, California, develops, manufactures and sells technically difficult generic and proprietary injectable, inhalation and intranasal medicines. It makes more than 30 products, and its own active pharmaceutical ingredients (including insulin API) through a subsidiary in China. The largest sellers are BAQSIMI, the nasal glucagon rescue spray bought from Eli Lilly in 2023, the over-the-counter asthma inhaler Primatene MIST, and hospital staples such as epinephrine, lidocaine and glucagon kits. Most volume flows through group purchasing organizations, wholesalers and retailers.

The latest reported quarter, Q3 2026 (reported November 5, 2026), was a record: net revenue of ~$207.6 million rose ~8% year over year and ~13% from Q2, GAAP net income was ~$37.8 million, and adjusted EPS of $1.14 (up from $0.93) beat the ~$0.86 consensus, a second straight beat after Q2's $0.91 against ~$0.61. BAQSIMI hit a record ~$58.8 million, up ~10% on volume, and Primatene MIST a record ~$31.5 million, up ~9%, while the new ipratropium inhaler (~$6.6 million, still the only generic on the market) and teriparatide (~$6.4 million) added growth. Glucagon kits fell ~37% and epinephrine ~19%, the latter because of slower releases from the IMS plant under FDA remediation. Gross margin slipped to ~48% from ~51% on lower net pricing and remediation costs of about $2-3 million in the quarter. Over the trailing twelve months revenue is ~$746 million and GAAP net income ~$99 million. Management expects Q4 2026 sales to grow in the high single digits from Q4 2025, declined to give 2027 guidance, and the board added $50 million to the buyback authorization.

The investment picture is a contest between a cheap multiple and a shrinking legacy base. At $28.15 on November 20, 2026 the market value is ~$1.2 billion, after heavy buybacks (~$74 million in the first half of 2026 alone). That is ~13x trailing GAAP EPS of ~$2.18 and ~8.4x forward EPS of ~$3.35. Against that, the South El Monte plant has been under an FDA warning letter since July 2026, BAQSIMI net pricing still faces 340B and rebate pressure even as volumes grow, and the biosimilar insulin aspart and a GLP-1 generic are not expected to sell until 2027. The shares have climbed from below $20 before the Q2 report to $28.15 (up ~6% year to date and ~11% over one year, 52-week range $16.65 to $31.00), above the ~$24.50 average of six analyst targets.

What's driving Amphastar Pharmaceuticals, Inc. (AMPH)?

1. BAQSIMI volume versus net price

BAQSIMI is the single largest product, at a record ~$58.8 million in Q3 2026 (up ~10% year over year) after ~$45.5 million in Q2 and ~$185 million in 2025. Unit volume drove the gain, though duplicate 340B discounts still cost ~$2.2 million of net price in the quarter. Management has cited peak sales potential of ~$250 to ~$275 million and has been exiting several unprofitable international markets since July to focus on the US. Hitting the first $175 million contract-year milestone triggered a $100 million payment to Lilly due in Q3 2026, so continued volume growth matters both for revenue and for justifying that acquisition cost.

2. New generic and inhalation launches

Launches are carrying the growth. Generic ipratropium bromide HFA, approved in February 2026 with 180 days of first-filer exclusivity, sold ~$8.4 million in its first quarter and ~$6.6 million in Q3, and Amphastar is still the only generic on the market. Teriparatide (launched December 2025) sold ~$6.4 million in Q3, iron sucrose (August 2025) keeps adding volume, and Primatene MIST set a record at ~$31.5 million on a price increase and higher volume. These products carry higher margins than the legacy book. The open question is durability: ipratropium exclusivity is time-limited, and generic pricing typically compresses as more entrants arrive. Q3 gross margin of ~48%, down from ~51%, shows pricing and plant costs already working against the mix.

3. Insulin biosimilars and the 2027 pipeline

The largest long-term lever is insulin. Amphastar makes its own insulin API and has a biosimilar insulin aspart (AMP-004) on file with the FDA, plus a GLP-1 generic ANDA (AMP-018), with commercialization for both expected in 2027 and no firm launch date. The company says its filed and in-development generics and biosimilars target US markets worth more than ~$6 billion combined by IQVIA data. Management has described the GLP-1 generic as a limited opportunity because of competition and noted three or four competing insulin aspart products, so the insulin approval is the bigger swing factor. Two other filings, AMP-005 and AMP-017, slipped from the first half to the second half of 2027, and AMP-104, a lower-global-warming Primatene MIST formulation, is targeted for filing by the end of 2028.

4. Cash flow and buybacks

Amphastar generated ~$175 million of operating cash flow over the trailing twelve months, including ~$43 million in Q3 2026, but free cash flow was only ~$9 million after capital spending and the BAQSIMI milestone. It has used cash aggressively on its own stock: shares outstanding fell to ~42.5 million at July 31, 2026 from ~47 million a year earlier, the first half of 2026 saw ~$74 million of repurchases, and in November the board authorized another $50 million. Total debt is ~$692 million (mostly 2029 convertible notes and a term loan) against ~$231 million of cash at September 30. A shrinking share count supports per-share earnings even when net income is flat, which is part of why adjusted EPS beat estimates.

What are the risks to Amphastar Pharmaceuticals, Inc. (AMPH)?

Legacy erosion is the most visible risk: glucagon kit sales fell ~37% in Q3 2026 on competition, and epinephrine fell ~19% as releases from the IMS plant slowed. BAQSIMI net pricing is under pressure from rebates, 340B discounts and payer mix, so prescription growth does not translate one-for-one into revenue. Regulatory risk rose in July 2026 when the FDA issued a warning letter to the IMS plant in South El Monte, California, citing cGMP problems in investigations, environmental monitoring and equipment; production continues, but remediation cost about $2-3 million in Q3, management expects somewhat higher costs for the next two or three quarters, backorders stood at ~$12.5 million, and the FDA can take further action. Pipeline timing is uncertain, since insulin aspart already passed an earlier Q1 2026 goal date without approval and two other filings slipped into the second half of 2027. The balance sheet carries ~$692 million of debt against ~$231 million of cash. Two founders and executives have pledged shares as loan collateral, and a forced sale by a lender could pressure the stock; insiders also sold about $1.1 million of shares in November 2026 filings. Tariffs, drug pricing reform and Chinese API exposure add policy risk, and the stock trades above the average analyst target after a ~28% three-month rally.

What is the Amphastar Pharmaceuticals, Inc. (AMPH) forecast?

6 analysts publish price targets on AMPH, averaging $24.50 as of November 2026, or -13.3% against the $28.25 share price on November 20, 2026. The published targets run from $20.00 to $30.00, a moderate spread, and the ratings split 0 buy, 6 hold, 1 sell. Over the last six months there have been 3 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full AMPH forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is AMPH a buy or a sell?

We give no verdict on Amphastar Pharmaceuticals, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. BAQSIMI volume versus net price. BAQSIMI is the single largest product, at a record ~$58.8 million in Q3 2026 (up ~10% year over year) after ~$45.5 million in Q2 and ~$185 million in 2025. The most optimistic published target, $30.00, assumes this works close to its best case.

The case against. Legacy erosion is the most visible risk: glucagon kit sales fell ~37% in Q3 2026 on competition, and epinephrine fell ~19% as releases from the IMS plant slowed. The most pessimistic target, $20.00, is roughly what AMPH is worth if this bites instead.

Read the full bull and bear case on AMPH, including what would have to change to break either one. Walnut is not an investment adviser.

How is Amphastar Pharmaceuticals, Inc. (AMPH) valued?

Market cap, P/E and dividend yield at today's price are in the AMPH key stats above. The business figures below come from Amphastar Pharmaceuticals, Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$746 million
  • Revenue growth (Q3 2026, YoY): ~8%
  • GAAP net income (TTM): ~$99 million
  • Q3 2026 adjusted EPS: $1.14 (vs ~$0.86 expected)
  • Gross margin (Q3 2026): ~48%
  • Total debt / cash: ~$692 million / ~$231 million

As of November 2026: Priced at the $28.15 close on November 20, 2026, Amphastar trades near 13x trailing GAAP earnings, 8.4x forward estimates and about 8.4x EV/EBITDA. The gap between GAAP and adjusted earnings comes mainly from amortization of the BAQSIMI intangible and share-based compensation. Net debt is roughly ~$460 million, and the six analysts in the consensus rate the stock Hold on average with a mean target of ~$24.50, below the current price.

Who competes with Amphastar Pharmaceuticals, Inc. (AMPH)?

Generic injectable makers

Hikma, Fresenius Kabi, Pfizer's Hospira unit, Teva and Viatris compete with Amphastar's hospital injectables such as epinephrine, lidocaine, naloxone and sodium bicarbonate. These are larger, multi-plant suppliers that bid for the same GPO contracts, so pricing hinges on shortages, number of entrants and manufacturing reliability, the area the FDA warning letter puts in focus.

Glucagon and diabetes rescue

Xeris Biopharma's Gvoke ready-to-use glucagon, Zealand Pharma's dasiglucagon, and legacy glucagon kits from Lilly, Novo Nordisk and generic makers compete with BAQSIMI and Amphastar's own glucagon kit. The shift toward ready-to-use products helps BAQSIMI but is the main reason Amphastar's traditional glucagon kit sales are falling sharply.

Inhalation and insulin biosimilars

Teva, Cipla and Lupin sell generic albuterol and other inhalers against Amphastar's albuterol, ipratropium and Primatene MIST franchise. In insulin, Biocon and Viatris (Semglee), Sandoz and nonprofit Civica target the same biosimilar opportunity as AMP-004, while Novo Nordisk, Lilly and Sanofi defend branded insulins with their own lower-priced versions.

What stocks are similar to Amphastar Pharmaceuticals, Inc. (AMPH)?

Other names that sit close to AMPH: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Amphastar Pharmaceuticals, Inc. (AMPH)

There are three common ways to get AMPH exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so AMPH sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where AMPH fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Amphastar Pharmaceuticals, Inc. (AMPH)

AMPH is a cash-generating specialty generics and branded-product company priced at ~13x trailing GAAP and ~8.4x forward earnings. The case rests on new launches and record BAQSIMI and Primatene MIST sales outrunning legacy erosion, plant remediation costs and the wait for 2027 insulin approvals.

More on Amphastar Pharmaceuticals, Inc. (AMPH)

Whether AMPH is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AMPH a buy or a sell?, and where the stock could go from here in the AMPH stock forecast.

For income investors, whether AMPH pays a dividend and how the payout looks is covered in does AMPH pay a dividend? And to weigh AMPH against a peer, read the full side-by-side comparisons: AMPH vs PFE and AMPH vs VTRS.

Wondering how AMPH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Amphastar Pharmaceuticals, Inc.

Ask Walnut's AI anything about AMPH and see how it fits what you own.

FAQ

What does Amphastar Pharmaceuticals do?

+

Amphastar develops, manufactures and sells technically challenging generic and proprietary medicines in injectable, inhalation and intranasal forms. It sells more than 30 products, including BAQSIMI nasal glucagon for severe low blood sugar, the over-the-counter Primatene MIST asthma inhaler, hospital injectables such as epinephrine and lidocaine, and newer generics including ipratropium bromide, iron sucrose and teriparatide. It also makes active pharmaceutical ingredients, including insulin, through its ANP subsidiary in China. Most sales go through group purchasing organizations, drug wholesalers and retailers in the US. Revenue over the trailing twelve months is ~$746 million. The company is headquartered in Rancho Cucamonga, California, and is led by co-founder and CEO Dr. Jack Zhang. Founders and insiders own a meaningful stake, which keeps strategy closely tied to management's long-term view.

How did Amphastar's latest quarter go?

+

In Q3 2026, reported November 5, 2026, net revenue was a record ~$207.6 million, up ~8% year over year and ~13% from Q2. GAAP net income was ~$37.8 million, and adjusted EPS was $1.14 against estimates near $0.86 and $0.93 a year earlier. BAQSIMI (~$58.8 million, up ~10%) and Primatene MIST (~$31.5 million, up ~9%) both set records, and ipratropium (~$6.6 million) and teriparatide (~$6.4 million) added growth. Glucagon kits fell ~37% and epinephrine ~19%. Gross margin fell to ~48% from ~51% on lower net pricing and IMS remediation costs. Management guided Q4 sales to high single digit growth, added $50 million to the buyback, and the stock rose sharply after the report.

How has AMPH stock performed in 2026?

+

AMPH closed at $28.15 on November 20, 2026, up about 6.4% year to date and 11% over one year. Most of that came late: the shares rose about 28% over three months and 12% in the past month after the Q2 and Q3 earnings beats. The 52-week range is $16.65 to $31.00.

How much is BAQSIMI worth to Amphastar?

+

BAQSIMI is the largest single product, at ~$185 million in 2025 sales and a record ~$58.8 million in Q3 2026, up ~10% year over year and over a quarter of revenue. Amphastar bought it from Eli Lilly in 2023 for an upfront payment plus milestones. In the contract year ended mid-2026 it reached ~$175 million in sales, triggering a $100 million milestone payment to Lilly due in Q3 2026. Volume growth drove the Q3 gain, while duplicate 340B discounts still reduced net price by ~$2.2 million. Management has cited ~$250 to ~$275 million of peak sales potential and has been exiting several unprofitable international markets since July 2026 to focus on the US. The asset is amortized on the income statement, which is a large part of the gap between GAAP and adjusted earnings.

What is the FDA warning letter about?

+

On July 2, 2026, Amphastar's IMS subsidiary received an FDA warning letter covering its South El Monte, California manufacturing plant, following an inspection in December 2025. It cites violations of current Good Manufacturing Practice related to investigation procedures, environmental monitoring and handling, and manufacturing equipment. The letter does not order the plant to stop or restrict production and does not require a further recall, so IMS continues to supply products while it remediates. Remediation cost about $2-3 million in Q3 2026 and slowed epinephrine releases; management expects somewhat higher costs over the next two or three quarters and said capacity is close to being restored. Until the FDA is satisfied, it can take further regulatory action, and unresolved warning letters can delay approvals tied to the site. Investors will be watching for any FDA close-out letter or reinspection news in coming quarters.

Is AMPH stock cheap?

+

On trailing numbers it screens inexpensively. At $28.15 on November 20, 2026 the market value is ~$1.2 billion, about ~13x trailing GAAP EPS of ~$2.18 and ~8.4x forward EPS of ~$3.35, low for a company with ~47% gross margins and ~$175 million of yearly operating cash flow. The discount reflects real issues: shrinking legacy products, BAQSIMI net pricing pressure, an FDA warning letter, ~$692 million of debt and insulin approvals that are not expected to generate sales until 2027. Analysts mostly rate the stock Hold, with an average target of ~$24.50, below the current price after a rally from under $20 in early August. Whether it is cheap depends on whether launches outrun erosion; the record Q3 helped that case.

What is in Amphastar's pipeline?

+

Amphastar has one ANDA and one biosimilar insulin candidate on file with the FDA, targeting US markets of more than ~$1.6 billion combined. The headline candidates are AMP-004, a biosimilar insulin aspart, and AMP-018, a GLP-1 generic, both now expected to be commercialized in 2027. It also has two biosimilars in development targeting markets over ~$3.5 billion and three generics targeting more than ~$1.2 billion. On the proprietary side it has in-licensed three peptides aimed at oncology and ophthalmology and a fully synthetic corticotropin compound (AMP-110) for inflammatory and autoimmune conditions. Management has said the GLP-1 market will be crowded, so insulin is the larger opportunity. Pipeline approvals can slip: the earlier insulin aspart goal date passed without approval, and in November 2026 the company moved the AMP-005 and AMP-017 filings to the second half of 2027. AMP-104, a new Primatene MIST formulation, is targeted for filing by the end of 2028.

Does Amphastar pay a dividend or buy back stock?

+

Amphastar does not pay a dividend. It returns cash through share repurchases instead, and has done so heavily. Shares outstanding fell to ~42.5 million at July 31, 2026 from roughly 47 million a year earlier, the company spent ~$74 million on buybacks in the first half of 2026, including ~$30 million in Q1, and in November 2026 the board authorized another $50 million. The 2023 convertible note offering also funded a $50 million repurchase. Buybacks lift earnings per share even when net income is flat, which helped adjusted EPS beat estimates in Q2 and Q3 2026. The tradeoff is balance-sheet flexibility, since total debt is ~$692 million against ~$231 million of cash after the $100 million BAQSIMI milestone owed to Lilly in Q3 2026.

How can I get exposure to AMPH?

+

AMPH trades on the Nasdaq and can be bought as individual shares, or fractional shares, through most US brokerages. It is a small-cap stock at ~$1.2 billion, so it also appears in small-cap and healthcare index funds such as Russell 2000 and pharmaceutical sector ETFs, where its weight is usually small. Investors who hold it directly often pair it with other specialty pharma or generic names to spread single-company risk, since one FDA action or a pricing change at BAQSIMI can move the shares sharply. Walnut can show how AMPH fits alongside the rest of a connected portfolio and how it has performed against the S&P 500. Walnut is not an investment adviser, and this is not a recommendation. Position size relative to total holdings is a personal decision that depends on goals and risk tolerance.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Amphastar Pharmaceuticals, Inc.'s investor relations page or your broker before making investment decisions.